title: [The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration].
abstract: OBJECTIVE
  To study the level of patient compliance with Ranibizumab therapy and affecting factors.
  
  
  METHODS
  Medical records of 76 patients aged from 50 to 86 years (mean age 70.7 +/- 9.5 years) who underwent Ranibizumab treatment for neovascular age-related macular degeneration (AMD) during 2010-2014 were used. Demographic data, visual acuity, optical coherence tomography results were analyzed. Surgical interventions, regularity of postoperative follow-up and its outcomes were also taken into consideration.
  
  
  RESULTS
  The results showed high efficacy and safety of Ranibizumab therapy, though patient adherence varied significantly during the treatment course. More than 90% of patients demonstrated strong adherence to treatment in the phase of stabilization. During the follow-up period on a monthly basis and in the phase of maintenance therapy the level of compliance was 48.6% and 63.2% correspondingly. It is found that patient adherence depends on the duration of treatment, visual acuity of the contralateral eye, and functional results of the initial stage of the treatment (phase of stabilization). Four clinical examples are provided to illustrate the correlation between treatment efficacy and compliance.
  
  
  CONCLUSIONS
  Patient compliance with Ranibizumab antiangiogenic therapy for neovascular AMD improves its efficacy, ensuring maximum increase of visual acuity in the phase of stabilization and functional stability in the phase of maintenance therapy. Monthly performed follow-up allows early detection of disease recurrence and timely recommencement of the treatment.
authors.forename: E V
authors.initials: EV
authors.lastname: Bobykin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003710:Demography; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008501:Medical Records, Problem-Oriented / Q000706:statistics & numerical data; D055118:Medication Adherence / Q000523:psychology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D000069579:Ranibizumab; D012189:Retrospective Studies; D018570:Risk Assessment; D012426:Russia / Q000453:epidemiology; D041622:Tomography, Optical / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity; D016903:Drug Monitoring
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab